Login to Your Account



Glenmark moves MAb for celiac, atopic dermatitis into phase II

By T.V. Padma
Staff Writer

Monday, September 21, 2015
NEW DELHI – Glenmark Pharmaceuticals SA, a Swiss subsidiary of Mumbai, India-based Glenmark Pharmaceuticals Ltd., completed phase I trials in the Netherlands of BBR 830, a monoclonal antibody (MAb) that targets a class of activated immune cells that are involved in several autoimmune disorders.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription